Use of catheters with the AgION antimicrobial system in kidney transplant recipients to reduce infection risk

Transplantation Proceedings
H LoertzerP Fornara

Abstract

Microbial blood infection represents a high risk for immuno-suppressed patients. Of all catheter-related infections in the bloodstream, 90% result from the use of central venous catheters, the main cause being microbial colonization at the catheter's insertion point or the catheter hub. Between January 2003 and December 2004, 102 patients received a renal transplant including 57 who received a triple-lumen central venous catheter (CVC) during the procedure. Two catheters were used: a standard polyurethane catheter placed in the jugular veina or the subclavian veina for group I, and polyurethane catheters with the AgION antimicrobial system always placed in the subclavian veina for group II. Care and maintenance of the CVCs was standardized in both groups. After catheter removal, the tips were analyzed microbiologically. Of 57 (43.9%) CVCs, 25 were found to be contaminated. In the first group 24 out of 41 CVCs (58.5%) showed bacterial growth, whereas in group II only one catheter (6.6%) had a biofilm. The most common contaminant (18 out of 25, 72%) was Staphylococcus epidermidis. In group II, two patients had positive blood cultures yet a microbiologically sterile CVC. None of the catheters with the AgION antimicrobial system ha...Continue Reading

References

May 25, 1994·JAMA : the Journal of the American Medical Association·D PittetR P Wenzel
Dec 24, 1997·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·P LjungmanO Ringdén
Jan 26, 1999·JAMA : the Journal of the American Medical Association·D L VeenstraS D Sullivan
Sep 3, 1999·American Journal of Respiratory and Critical Care Medicine·B DigiovineM Higgins
Apr 15, 2000·Annals of Internal Medicine·R J SherertzE F Haponik
Sep 23, 2003·Critical Care Medicine·Cameron DezfulianSanjay Saint
Mar 12, 2004·Transplantation Proceedings·A A Al-Khader, F A M Shaheen
Dec 4, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Scott A McConnellElias J Anaissie
Jan 25, 2005·The American Journal of Emergency Medicine·Stephen TrzeciakKenneth J Pursell
Jul 20, 2005·The Journal of Hospital Infection·E W MorettiH P Wetzler

❮ Previous
Next ❯

Citations

Oct 18, 2007·Intensive Care Medicine·B S Niël-WeiseP J van den Broek
Apr 29, 2008·The Journal of Hospital Infection·B S Niël-WeiseP J van den Broek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.